Peptide CDMO Market
完整報告名稱與涵蓋範圍
Peptide CDMO Market Size, Share & Trends Analysis Report, By Service Type (Peptide API Manufacturing, Process and Analytical Development, Formulation and Drug Product Manufacturing, Regulatory and Clinical Supply Services), By Synthesis Technology (Solid-Phase Peptide Synthesis, Liquid-Phase and Hybrid Synthesis, Recombinant and Enzymatic Production), By Therapeutic Area (Metabolic and Endocrine Disorders, Oncology, Infectious Diseases, Cardiovascular and Other Areas), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The peptide CDMO market comprises contract development and manufacturing services for therapeutic peptides across all therapeutic areas, covering process development, GMP active ingredient production by solid-phase, liquid-phase, hybrid, recombinant or enzymatic routes, drug product formulation and regulatory support. Research-grade custom peptides for discovery and in-house manufacturing by originators are excluded.
Peptide therapeutics have moved from a niche to one of the fastest-growing modality classes, with incretin drugs, radioligand precursors, peptide-drug conjugates, cyclic and stapled peptides and oral peptides all expanding the pipeline. Sponsors increasingly outsource because peptide synthesis requires specialised equipment, purification and analytical expertise, and because commercial demand for metabolic peptides has absorbed much of the industry's capacity. Providers are investing in large-scale synthesis trains, continuous chromatography, greener solvent systems and liquid-phase technologies, while regulators sharpen expectations on impurity control and comparability for complex peptide generics.
Switzerland, Germany, the United States and Japan remain centres of high-end capacity, while China, Taiwan and India expand cost-competitive production for generics and emerging markets. Competition involves dedicated peptide specialists, integrated global CDMOs and a rising cohort of Asian manufacturers targeting both API and finished dose.
The InsightAce study provides US$ revenue forecasts for every service type, synthesis technology, therapeutic area and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide CDMO Market Snapshot
Chapter 4. Global Peptide CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Peptide API Manufacturing
5.2.2. Process and Analytical Development
5.2.3. Formulation and Drug Product Manufacturing
5.2.4. Regulatory and Clinical Supply Services
Chapter 6. Market Segmentation 2: By Synthesis Technology Estimates & Trend Analysis
6.1. Synthesis Technology & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Synthesis Technology:
6.2.1. Solid-Phase Peptide Synthesis
6.2.2. Liquid-Phase and Hybrid Synthesis
6.2.3. Recombinant and Enzymatic Production
Chapter 7. Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
7.1. Therapeutic Area & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
7.2.1. Metabolic and Endocrine Disorders
7.2.2. Oncology
7.2.3. Infectious Diseases
7.2.4. Cardiovascular and Other Areas
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical Companies
8.2.2. Biotechnology Companies
8.2.3. Generic Manufacturers
Chapter 9. Peptide CDMO Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Bachem Holding AG
11.2. PolyPeptide Group AG
11.3. CordenPharma International
11.4. Lonza Group AG
11.5. WuXi AppTec (WuXi TIDES)
11.6. AmbioPharm, Inc.
11.7. Thermo Fisher Scientific Inc. (Patheon)
11.8. Piramal Pharma Solutions
11.9. Almac Group
11.10. CPC Scientific Inc.
11.11. Chengdu Shengnuo Biotec Co., Ltd.
11.12. ScinoPharm Taiwan, Ltd.
11.13. Senn Chemicals AG
11.14. USV Private Limited
11.15. Ajinomoto Bio-Pharma Services
圖表清單 List of Tables & Figures
Table 1. Global Peptide CDMO Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global Peptide CDMO Market Segmentation and Scope Overview
Table 2. Global Peptide CDMO Market Revenue Forecast by Synthesis Technology, 2026-2035 (US$ Mn)
Figure 2. Global Peptide CDMO Market Share by Service Type, 2026 & 2035
Table 3. Global Peptide CDMO Market Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 3. Peptide Therapeutics Pipeline by Phase and Therapeutic Area, 2026
Table 4. Global Peptide CDMO Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Peptide CDMO Capacity Expansions and Technology Investments by Region
Table 5. Global Peptide CDMO Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Peptide CDMO Growth Opportunity Analysis
Table 6. North America Peptide CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Peptide CDMO Market Participants
Table 7. Europe Peptide CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Peptide CDMO Market
Table 8. Asia Pacific Peptide CDMO Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Regulatory Expectations for Impurity Control in Complex Peptide Generics
Table 9. Strategic Developments of Leading Peptide CDMO Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們